Thursday, April 30, 2026
← Back to archivePolicy
Policy•STAT News•Apr 30, 2026
Opinion: Congress must hold RFK Jr. accountable after hearings
background ▾
- •The CDC's top vaccine advisory committee has been entirely restructured by HHS under Kennedy, with a federal court recently pausing operations and calling the committee's actions 'arbitrary and capricious'—creating uncertainty in the framework physicians and insurers rely on for vaccine guidance
- •Disease surveillance systems are failing to track even endemic diseases like measles effectively, with state reporting lagging real-time transmission—raising questions about preparedness for emerging threats
- •Congressional oversight of HHS vaccine and public health policy under Kennedy appears insufficient, with specific policy details on disease surveillance and vaccine advisory integrity not adequately addressed in recent hearings
measles vaccine
→ Read original articlePolicy•STAT News•Apr 30, 2026
HHS appeals ruling that stalled many of Kennedy’s vaccine policy changes
background ▾
- •A federal judge ruled Kennedy's vaccine policy changes likely violated the Administrative Procedures Act, blocking their implementation—the DOJ's appeal prolongs legal uncertainty around the government's ability to alter vaccine recommendations and advisory committee composition.
- •The HHS charter revision appears designed to preempt appellate arguments by adding expertise categories and organizations aligned with Kennedy's vaccine skepticism, suggesting a coordinated legal strategy that may complicate the court's review.
- •Watch for: First Circuit appellate decision timeline; whether the revised charter successfully insulates the policy changes from legal challenge; any further White House guidance on Kennedy's vaccine initiatives given reported internal steering away from vaccine focus.
American Association of PediatricsChildren's Health Defense
→ Read original articlePolicy•KFF•Apr 30, 2026
Medicaid and CHIP Eligibility, Enrollment, and Renewal Policies as States Prepare for Major Medicaid Policy Changes
background ▾
- •Starting January 2027, Medicaid expansion states must implement work/community engagement requirements for expansion populations and shift to semi-annual renewals, representing a major structural shift in program administration
- •The law eliminates Medicaid eligibility for certain lawfully residing immigrants (asylees, refugees, trafficking victims) effective October 2026, narrowing coverage to primarily green card holders and specific humanitarian populations
- •States face concurrent budget pressures and a 10-year delay in enforcement of 2024 enrollment simplification regulations, creating implementation challenges and potential for additional coverage restrictions beyond mandated changes
Policy•KFF•Apr 30, 2026
Medicaid Eligibility Levels for Older Adults and People with Disabilities (Non-MAGI) in 2026
background ▾
- •Non-MAGI Medicaid enrollees (older adults and people with disabilities) comprise only 20% of enrollees but consume over 50% of Medicaid spending, making them a critical population for pharma despite budgetary pressure from the 2025 reconciliation law
- •States have significant discretion over optional Medicaid eligibility for this population; 49 of 50 states offer optional coverage pathways, but upcoming federal funding reductions will likely incentivize eligibility restrictions or benefit cuts affecting drug access
- •Watch for state-by-state Medicaid policy changes in 2026-2027, particularly around optional eligibility pathways and formulary restrictions, which could substantially impact pharmaceutical utilization in geriatric and disability populations
Policy•Fierce Pharma•Apr 30, 2026
Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'
background ▾
- •FDA enforcement action targets advertising execution rather than drug safety or efficacy claims
- •Bayer must revise DTC promotional materials to comply with visual presentation standards
BayerNubeqa (darolutamide)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 29, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
background ▾
- •Teva's $700M+ acquisition of ecopipam represents a bet that existing Tourette treatments (alpha-2 agonists and antipsychotics) have inadequate efficacy-safety profiles, with alpha-2 agonist discontinuation rates as high as 61% in 3 months and parental reluctance to use long-term antipsychotics in pediatric patients
- •Ecopipam has completed phase 3 testing with positive efficacy data and an expected FDA submission in H2 2024, de-risking regulatory approval relative to earlier-stage acquisitions
- •Teva's success will depend on differentiated commercial execution in a small, rare-disease market (~100,000 affected children) and sustained physician/payer acceptance of a novel mechanism with limited post-approval real-world safety data
Teva PharmaceuticalsEmalex BiosciencesecopipamAustedoUzedy
→ Read original articleMarket Access•Fierce Biotech•Apr 29, 2026
Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology
background ▾
- •GSK's post-Walmsley strategy prioritizes acquiring late-stage assets designed to improve on existing blockbuster treatments rather than pursuing de novo innovation, with oncology identified as the most attractive therapeutic area.
- •The company has already deployed >$4B in dealmaking (Rapt, 35Pharma, IDRx) and signaled an active pipeline of acquisition targets in oncology, cardiovascular, and respiratory spaces, though CEO remained noncommittal on specific targets.
- •Watch for: Additional M&A announcements in oncology within the next 12-18 months; clinical readouts from mocertatug rezetecan in late-stage trials; indication of deal size/therapeutic areas in future earnings calls.
GSKNovartisRocheXolairWinrevairGleevec
→ Read original articleMarket Access•Fierce Biotech•Apr 30, 2026
AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M
background ▾
- •AstraZeneca exercised its option on PTX-299, committing to develop a novel EGFR degrader that targets a different mechanism than its blockbuster Tagrisso (tyrosine kinase inhibitor), potentially complementing rather than cannibalizing existing EGFR oncology sales.
- •Pinetree's AbReptor protein degradation platform received major pharma validation, suggesting targeted protein degradation (TPD) for oncology drug resistance remains a prioritized modality among large-cap developers.
- •Monitor PTX-299 clinical trial initiation timing and early efficacy/safety signals relative to competitive EGFR-targeted degraders; AstraZeneca's development speed and oncology infrastructure could accelerate time-to-clinic.
AstraZenecaPinetree TherapeuticsPTX-299Tagrisso
→ Read original articleMarket Access•Fierce Pharma•Apr 30, 2026
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
background ▾
- •Avalyn raised $300M (above IPO guidance), indicating strong investor confidence in its inhaled respiratory drug reformulation strategy
- •The company will deploy capital primarily toward late-stage clinical trials, suggesting a near-to-mid-term regulatory timeline
- •Success depends on demonstrating meaningful clinical or patient-convenience advantages for reformulated drugs in a crowded respiratory market
Avalyn Pharma
→ Read original articleMarket Access•Fierce Pharma•Apr 30, 2026
AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
background ▾
- •Skyrizi achieved $4.48 billion in Q1 2026 sales with 30.9% year-over-year growth, demonstrating sustained market strength despite J&J's Icotyde launch
- •AbbVie is actively defending Skyrizi against J&J competitive entry, indicating heightened competition in the plaque psoriasis market
- •Monitor upcoming quarterly results and market share data to assess whether Icotyde gains meaningful penetration or Skyrizi maintains dominance
AbbVieJohnson & JohnsonSkyriziIcotyde
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 29, 2026
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
background ▾
- •FDA clinical hold on U.S. enrollment in ENIGMA-TRS 2 phase 3 trial after patient death, though independent safety board and company assert death was unrelated to evenamide and recommend trial continuation
- •Newron faces significant competitive pressure in schizophrenia market after losing race to Bristol Myers Squibb's Cobenfy approval in 2024, making timeline delays particularly costly
- •Watch for: Resolution timeline for U.S. clinical hold, ENIGMA-TRS 1 enrollment progress in non-U.S. regions, and any interim safety data that could support or contradict continued development
Newron PharmaceuticalsEisaiEA PharmaevenamideCobenfy
→ Read original articleClinical Trials•Fierce Biotech•Apr 30, 2026
GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2
background ▾
- •Both molecules from the GSK-Alector partnership have failed: nivisnebart in phase 2 and latozinemab (which failed phase 3 in frontotemporal dementia), effectively invalidating the progranulin-elevation hypothesis as a therapeutic strategy for neurodegeneration.
- •Central nervous system penetration remains a fundamental unresolved challenge for antibody-based agonists targeting microglial receptors, limiting the class's clinical viability despite strong preclinical and genetic rationale.
- •Monitor Alector's next-wave blood-brain barrier technology: the company plans to file an IND for an anti-amyloid beta antibody in Q1 2025, with preclinical data described as 'initially promising' but clinical validation still distant.
GSKAlectorAbbVienivisnebartlatozinemab
→ Read original articleClinical Trials•Fierce Pharma•Apr 30, 2026
Pfizer looks to jump start Elrexfio with topline win in second-line myeloma
background ▾
- •Elrexfio demonstrates efficacy in second-line myeloma, potentially doubling its addressable patient population and differentiating it from competitors in a crowded bispecific market
- •Positive readout provides foundation for label expansion and could accelerate uptake of Pfizer's bispecific franchise
- •Watch for regulatory filing timeline, detailed efficacy/safety data at medical conferences, and competitive positioning against Janssen's talquetamab and other next-gen bispecifics
PfizerElrexfioteclistamab
→ Read original articleClinical Trials•Endpoints News•Apr 29, 2026
Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
background ▾
- •Elrexfio met its primary Phase 3 endpoint with statistically significant and clinically meaningful PFS improvement in multiple myeloma
- •This positive readout de-risks the program and likely supports imminent regulatory submission strategy
- •Watch for full data presentation at medical conferences and regulatory interactions around filing timeline and indication scope
PfizerElrexfio
→ Read original articleClinical Trials•Endpoints News•Apr 29, 2026
GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
background ▾
- •GSK has multiple Phase 3 readouts pending in 2024 that will inform potential team reorganization decisions
GSK
→ Read original article